Table 1.
Baseline Characteristics of Patients
| Characteristic | All patients (n=186) | NAFLD (n=106) | ALD (n=80) | p-value |
|---|---|---|---|---|
| Age, yr | 53.4±12.0 | 48.8±13.3 | 52.5±9.8 | 0.092 |
| Male sex | 143 (76.9) | 67 (63.2) | 76 (95.0) | <0.001 |
| BMI, kg/m2 | 26.4±3.5 | 26.8±3.7 | 25.8±3.3 | 0.102 |
| Current smoker | 47 (25.3) | 16 (15.1) | 31 (38.8) | <0.001 |
| Regular exercise | 99 (53.2) | 56 (52.8) | 43 (53.8) | 0.901 |
| LSM, kPa | ||||
| Mean | 7.0±4.0 | 7.0±4.3 | 7.0±3.5 | 0.611 |
| Median (IQR) | 5.9 (4.9–7.8) | 5.9 (4.8–7.7) | 5.9 (4.9–8.6) | 0.833 |
| CAP, dB/m | ||||
| Mean | 281.6±46.0 | 288.8±46.0 | 272.0±44.5 | 0.014 |
| Median (IQR) | 279.5 (251.0–313.3) | 293.0 (256.8–322.3) | 269.5 (244.5–299.0) | 0.008 |
| Steatosis grade in US | <0.001 | |||
| S1 | 75 (40.3) | 30 (28.3) | 45 (56.2) | |
| S2 | 76 (40.9) | 49 (46.2) | 27 (33.8) | |
| S3 | 35 (18.8) | 27 (25.5) | 8 (10.0) | |
| PLT, 109/L | 210.8±57.1 | 215.4±54.0 | 204.7±60.7 | 0.137 |
| PT INR | 0.97±0.09 | 0.96±0.05 | 0.98±0.12 | 0.884 |
| TC, mg/mL | 184.9±34.8 | 186.3±33.2 | 183.1±36.9 | 0.534 |
| TB, mg/dL | 0.79±0.46 | 0.80±0.57 | 0.78±0.28 | 0.083 |
| AST, U/L | 35.4±19.4 | 34.5±18.8 | 36.7±20.2 | 0.660 |
| ALT, U/L | 45.4±31.4 | 48.1±32.3 | 41.9±30.2 | 0.110 |
| ALP, U/L | 65.8±18.8 | 67.2±20.0 | 64.0±17.0 | 0.288 |
| GGT, U/L | 69.8±72.3 | 50.3±45.1 | 95.7±91.4 | <0.001 |
| Alb, g/dL | 4.6±0.2 | 4.6±0.2 | 4.6±0.2 | 0.330 |
Data are presented as mean±SD or median (interquartile range).
NAFLD, nonalcoholic fatty liver disease; ALD, alcoholic liver disease; BMI, body mass index; LSM, liver stiffness measurement; IQR, interquartile range; CAP, controlled attenuation parameter; US, ultrasound; S1, mild steatosis; S2, moderate steatosis; S3, severe steatosis; PLT, platelet; PT INR, prothrombin time international normalized ratio; TC, total cholesterol; TB, total bilirubin; AST, aspartate aminotransferase; ALT, alanine amino-transferase; ALP, alkaline phosphatase; GGT, γ-glutamyl transpeptidase; Alb, albumin.